How do SSRIs help patients with irritable bowel syndrome?

Gut

Volumn 55, Issue 8, 2006, Pages 1065-1067

  Creed, F ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; CLINICAL TRIAL; COLON DILATATION; DEPRESSION; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HIGH FIBER DIET; HUMAN; HYPERTENSION; IRRITABLE COLON; NOTE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; SEXUAL ABUSE; WELLBEING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; HUMANS; IRRITABLE BOWEL SYNDROME; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33746120837     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.086348     Document Type: Note

References (30)

1. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103.
2. Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Talley NJ, et al. Rome II. The functional gastrointestinal disorders:Diagnosis, pathophysiology and treatment; A multinational consensus, 2nd Edn. Virginia: Degnon and Associates, 2000:157-245.
3. Jackson JI, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with anti-depressants: A meta-analysis. Am J Med 2000;108:65-72.
4. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-20.
5. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-28.
6. Tack J, Broekaert D, Corsetti M, et al. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther 2006;23:265-74.
7. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-18.
8. Gorard DA, Libby GW, Farthing JG. Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-66.
9. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews. Oxford: Update Software, 2005;CD005454).
10. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137-45.
11. Moja PI, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches, Cochrane Database of Systematic Reviews. Oxford: Update Software, 2005;CD002919).
12. Aragona M, Bancheri L, Perinelli D, et al. Randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain 2005;9:33-8.
13. Clause RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005;54:1332-41.
14. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews. Oxford: Update Software, 2002;CD001396).
15. O'Molley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980-90.
16. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122:1140-56.
17. North CS, Downs D, Clause RE, et al. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004;2:787-95.
18. Miller AR, North CS, Clouse RE, et al. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30.
19. Spiegel BM, Kanwal F, Naliboff B, et al. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:2262-73.
20. Creed F, Guthrie E, Ratcliffe J, et al. Reported sexual abuse predicts impaired functioning but a good response to psychological treatments in patients with severe irritable bowel syndrome. Psychosom Med 2005;67:490-9.
21. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gostroenterology 2003;124:303-17.
22. Guthrie E, Barlow J, Fernandes L, North of England IBS Research Group, et al. Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome. Psychosom Med 2004;66:578-82.
23. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998;115:1263-71.
24. Kilkens TO, Honig A, Fekkes D, et al. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls. Aliment Pharmacol Ther 2005;22:865-74.
25. Talley NJ. SSRIs in IBS: sensing a dash of disappointment. Clin Gastroenterol Hepatol 2003;1:155-9.
26. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews. Oxford: Update Software, 2005;CD003460).
27. Creed F, Guthrie E, Ratcliffe J, North of England IBS Research Group, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust NZ J Psychiatry 2005;39:807-15.
28. Chitkara DK, Cremonini F, Talley NJ, et al. Psychotherapy and paroxetine: cost effective for severe IBS, or a waste of resources. Gastroenterology 2003;125:1554-5.
29. Hahn BA, Kirchdoerfer U, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553-9.
30. Creed F, Ratcliffe J, Fernandes L, North of England IBS Research Group, et al. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry 2005;186:507-15.